All articles tagged with #philip morris
A Russian ballistic missile hit a Philip Morris warehouse in eastern Ukraine’s Kharkiv region, sparking a fire over 5,000 square meters. More than 80 firefighters and 20 units battled the blaze; there were no casualties as staff sheltered inside.
Philip Morris International's stock dropped over 7% after missing quarterly sales estimates, despite a 7.1% revenue increase and an upward revision of its full-year earnings outlook, as cigarette shipment volumes declined and demand for traditional cigarettes continued to fall, though sales of smoke-free products grew significantly.
Philip Morris stock declined 2.82% in pre-market trading after reporting mixed Q2 2025 results, with adjusted EPS of $1.91 beating estimates but revenue of $10.1 billion missing expectations. The company raised its full-year EPS guidance to $7.43-$7.56, likely surpassing Wall Street estimates, and maintains a 'Strong Buy' analyst rating with a target price of $197.11, indicating a potential 9.21% upside.
Philip Morris International plans to invest $600 million in a new Colorado plant to meet rising demand for Zyn nicotine pouches, creating 500 jobs by 2025. The company acquired Zyn owner Swedish Match in 2022 to expand its smoke-free offerings. Despite increased revenues and Zyn's popularity among young adults, the product faces legal challenges and health warnings due to nicotine addiction risks.
Philip Morris International is investing $600 million in a new Zyn nicotine pouch manufacturing facility in Aurora, Colorado, expected to create 500 local jobs and 5,000 construction jobs. The facility aims to meet the growing demand for smokeless nicotine alternatives and is projected to have a $550 million annual economic impact. The company also announced significant donations to support Colorado veterans and local housing initiatives. Concerns remain about the potential appeal of nicotine pouches to underage users, although current data shows low usage among teens.
Philip Morris International is investing $600 million to build a new production facility in Aurora, Colorado, to manufacture Zyn nicotine pouches, addressing nationwide shortages. The facility will create 500 direct jobs and have a significant economic impact. This move aligns with PMI's mission to provide better alternatives to traditional cigarettes.
Philip Morris International Inc. is investing $600 million in a new manufacturing facility in Aurora, Colorado, to increase production of Zyn, a popular oral nicotine pouch facing high demand. The plant will start operations by the end of next year, with regular production beginning in 2026.
Philip Morris International reported quarterly earnings that exceeded expectations, but revenue fell short as sales of its heated tobacco and oral nicotine products remained strong. The company raised its full-year adjusted earnings guidance and cited its IQOS heated tobacco products and Zyn oral nicotine pouch as growth drivers. Philip Morris has been shifting away from traditional cigarettes towards smoke-free products and respiratory medicines. While shipment volume for traditional cigarettes declined, net revenue for the category increased due to higher pricing. The company's Zyn nicotine pouch unit saw significant shipment volume growth.
Philip Morris' earnings outlook falls short of expectations, with the company reporting disappointing results and a shortfall in projected earnings.
Massachusetts' Supreme Judicial Court upheld a nearly $37 million judgment for Patricia Walsh Greene, who claimed she developed lung cancer after switching from Marlboro Red cigarettes to Marlboro Lights because she thought they were less dangerous. The court found that Philip Morris' claim that Marlboro Lights were safer was false, and internal research conducted by the company in the late 1970s showed that the smoke from Marlboro Light cigarettes was actually worse. The court confirmed the jury did have sufficient evidence of Philip Morris conspiring with other cigarette manufacturers in a manner that did ultimately cause Greene's cancer and subsequent kidney failure.